07:47 AM EDT, 05/20/2024 (MT Newswires) -- Dyne Therapeutics ( DYN ) said Monday that new data from its ongoing phase 1/2 trials of DYNE-101 in patients with myotonic dystrophy type 1 and DYNE-251 in patients with Duchenne muscular dystrophy showed "compelling impact" on key disease biomarkers alongside improvements in various functional endpoints and favorable safety profiles.

The company said DYNE-101 demonstrated consistent splicing correction across all patients in the phase 1/2 trial, along with improvements in myotonia and muscle strength, among others. Meanwhile, DYNE-251 exceeded the standard of care in dystrophin expression, Dyne Therapeutics ( DYN ) added.

Dyne Therapeutics ( DYN ) said it continues to seek accelerated approvals for both the DYNE-101 and DYNE-251 programs and expects to issue registration updates by the end of the year.

Dyne Therapeutics ( DYN ) shares were up nearly 12% in recent Monday premarket activity.

Price: 30.97, Change: +3.29, Percent Change: +11.89